Literature DB >> 22665530

Characterization of potential CD138 negative myeloma "stem cells".

Jacob H Christensen, Pia V Jensen, Ida B Kristensen, Niels Abildgaard, Marianne Lodahl, Thomas Rasmussen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22665530      PMCID： PMC3366666          DOI： 10.3324/haematol.2011.043125

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules.

Authors:  N S Ihrcke; J L Platt
Journal:  J Cell Physiol       Date:  1996-09       Impact factor: 6.384

2.  Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1.

Authors:  J Reiland; V L Ott; C S Lebakken; C Yeaman; J McCarthy; A C Rapraeger
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

3.  Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.

Authors:  Gwenny M Fuhler; Mirjam Baanstra; Daniel Chesik; Rajesh Somasundaram; Anja Seckinger; Dirk Hose; Maikel P Peppelenbosch; Nico A Bos
Journal:  Exp Cell Res       Date:  2010-03-20       Impact factor: 3.905

4.  Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Authors:  Karène Mahtouk; Dirk Hose; Pierre Raynaud; Michael Hundemer; Michel Jourdan; Eric Jourdan; Veronique Pantesco; Marion Baudard; John De Vos; Marion Larroque; Thomas Moehler; Jean-Francois Rossi; Thierry Rème; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

5.  The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.

Authors:  M Jourdan; M Ferlin; E Legouffe; M Horvathova; J Liautard; J F Rossi; J Wijdenes; J Brochier; B Klein
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

6.  Characterization of clonogenic multiple myeloma cells.

Authors:  William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

7.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Authors:  William Matsui; Qiuju Wang; James P Barber; Sarah Brennan; B Douglas Smith; Ivan Borrello; Ian McNiece; Lan Lin; Richard F Ambinder; Craig Peacock; D Neil Watkins; Carol Ann Huff; Richard J Jones
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro.

Authors:  C H Homburg; M de Haas; A E von dem Borne; A J Verhoeven; C P Reutelingsperger; D Roos
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

9.  Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.

Authors:  Yang Yang; Veronica Macleod; Hua-Quan Miao; Allison Theus; Fenghuang Zhan; John D Shaughnessy; Jeffrey Sawyer; Jin-Ping Li; Eyal Zcharia; Israel Vlodavsky; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2007-03-08       Impact factor: 5.157
  9 in total
  5 in total

Review 1.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

2.  Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Authors:  Teri A Oldaker; Paul K Wallace; David Barnett
Journal:  Cytometry B Clin Cytom       Date:  2015-09-04       Impact factor: 3.058

3.  Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

Authors:  Teresa Paíno; María E Sarasquete; Bruno Paiva; Patryk Krzeminski; Laura San-Segundo; Luis A Corchete; Alba Redondo; Mercedes Garayoa; Ramón García-Sanz; Norma C Gutiérrez; Enrique M Ocio; Jesús F San-Miguel
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

4.  Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Authors:  Alboukadel Kassambara; Matthieu Schoenhals; Jérôme Moreaux; Jean-Luc Veyrune; Thierry Rème; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

5.  Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.

Authors:  Alejandra Leivas; Ruth M Risueño; Alma Guzmán; Laura Sánchez-Vega; Manuel Pérez; Diego Megías; Lucía Fernández; Rafael Alonso; Antonio Pérez-Martínez; Inmaculada Rapado; Joaquín Martínez-López
Journal:  Cancer Immunol Immunother       Date:  2021-03-10       Impact factor: 6.968
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.